• Spearheaded 6 new product development initiatives driving a strategy to bring specialist-level medicine directly into customer clinics via the Zoetis Virtual Laboratory, an innovative ecosystem of diagnostic products and services that empowers fast treatment decisions. This included financials, branding, positioning, and messaging focused on customers gaining deeper insights to enhance patient care.• Led the development and execution of 5 comprehensive, long-term strategic plans for new and end-of-life products, leveraging in-depth market research and competitive analysis to identify opportunities for market share growth. Collaborated cross-functionally with product management, marketing, sales, and operations teams to align strategic objectives and establish clear, measurable goals. • Headed-up the strategic prioritization of diagnostic assays by conducting a comprehensive landscape analysis, meticulously mapping competitive offerings, while considering factors such as medical need, customer workflow, and financials. The output is a strategic overview that drives informed decision-making, optimizes the test portfolio for new product development, and is easily updatable.• Orchestrated a highly effective new product transfer meeting with 75 colleagues, enabling markets to begin launch preparations.• Ensured customer-centric new product development and commercialization initiatives by leading routine Global Asset Team meetings with 50 colleagues representing marketing, veterinary operations, product development, regulatory, and commercial development.• Implemented a new systematic approach to align product launch timing with business unit functional leadership monthly. A comprehensive view of these initiatives enabled one source of information tracked by market, ensuring coordinated global rollouts.• Articulated the commercial considerations that supported new business development licensing activities, driving strategic partnerships.

• Drove the global leadership of the #1 global vaccines portfolio significantly ahead through increased penetration of base products, expansion into new markets, new product growth, and improved coordination with marketing and veterinary colleagues in each market.• Charted out a highly aggressive long-term strategy for China via strategic leadership meetings in Shanghai and Beijing enabling them to extend their #1 share position. This included focus by species, disease, form of vaccine delivery, and novel combination vaccines.• Spearheaded company-wide Zoetis Call for Studies process, ensuring the voice of all key markets was heard in the annual lifecycle prioritization, which I effectively communicated and championed throughout the organization, driving cohesive strategic alignment.• Achieved first to market COVID-19 vaccine launch enabling Zoetis to be at the forefront of protecting the health and well-being of more than 100 mammalian species living in nearly 70 zoos, as well as safeguarding inhabitants in a dozen conservatories.• Led the creation of a comprehensive global vision, key strategies, and action items for all commercial development initiatives. • Hosted the 2021 Innovation Summit, which uncovered several strategic therapeutic and preventative lifecycle opportunities.• Gained R&D endorsement on eight global asset growth strategies developed across canine and feline infectious disease categories.• Received eight Core Belief Recognitions and two Veterinary Medical R&D Impact Awards highlighting significant contributions.

• Spearheaded the global launch of Simparica Trio®, the #1 Zoetis product in terms of annual sales, a broad-spectrum chewable tablet for dogs formulated to kill fleas, ticks, roundworms, hookworms, and to prevent heartworm and lungworm disease.• IHS Market Connect recognized Zoetis' Simparica Trio as the Best New Companion Animal Product for 2020. This accolade underscored its exceptional market reception, surpassing initial launch expectations. By 2023, sales had surged past $800+ million.• Developed a holistic and strategic marketing package for global markets well in advance of Simparica Trio launches, which was extremely well received. This included positioning, branding, collateral, advertisements, posts, website, emails, and digital banners.• Progressed new product opportunities, shifting Zoetis Parasiticides share from #4 in 2020 to #1 share in 2023.• Headed up the Parasiticides Global Asset Team ensuring that the voice of the customer was fully understood in new product activities.• Received four Core Belief Recognitions related to new parasiticides product development and commercialization activities.

• Gave the portfolio a quantum leap forward by developing, accelerating, and introducing 11 new and innovative vaccine SKUs to help prevent Canine Lyme disease, Canine Influenza Virus (CIV), and Canine Infectious Respiratory Disease (CIRD).• Increased Lyme disease market share from #4 to #1 by introducing Vanguard® crLyme to provide broad spectrum coverage. • First to market with Vanguard® CIV H3N2 to address flu outbreaks with a quick follow-up extension Vanguard® CIV H3N2/H3N8.• Gained leadership alignment to consolidate six brands into one and hired the packaging design firm which executed the strategy. This effort simplified the product selection for customers, reduced potential route of administration errors, provided a better understanding of what each vaccine does, and dramatically increased Vanguard® brand recognition, product equity, and sales.• Drove B2B and B2C marketing campaign through an Immunity Toolbox with resources to support veterinary hospitals and pet owners (e.g. diagnostic algorithms, educational materials, pet owner guides, waiting room videos, social media resources).• Developed omnichannel marketing campaigns creating a cohesive brand experience targeted to key opinion leaders, veterinarians, pet owners, and group purchase organization members, across conference booths, signage, sales collateral, including traditional media such as advertisements and public relations and digital including social media, websites, email, and banner advertisements.• Selected for the Emerging Leaders program. Received 10 Core Belief Recognitions, Lead Dog Award, six Vetty Awards, Marketing Excellence Award, and the President’s Circle Award. Achieved multiple #1 ranked Marketing sessions at National Sales Meetings.

Associate Director of Marketing, ConvaTec Wound Therapeutics (spun off from Bristol-Myers Squibb)• Launched AQUACEL® Foam five-layer cover dressing with 99% of the sales force colleagues noting an effective launch.• Previously headed up the pilot launch team which exceeded the sales objective by 80% and optimized the narrative with customers. • Launched AQUACEL® Ag Burn, a highly innovative antimicrobial dressing customized for burn victims with gloves and large sizes.Senior Product Manager, Skin Care • Exceeded the sales target significantly and achieved double the category growth by strategically repositioning the Sensi-Care® brand to emphasize extra protection for high-risk skin and the Aloe Vesta® brand to highlight essential everyday preventive care.• Successfully integrated Septi-Soft® shampoo into the Sensi-Care® line, optimizing marketing resources behind one less brand.• Developed and implemented a simplified three-step protocol for clinicians and patients (#1 Cleanse, #2 Moisturize, #3 Protect). Product Manager, AQUACEL® Ag Antimicrobial • Exceeded budget by growing sales 80%, received a Global Oscar Award, and won the Global Best Practices contest in Paris, France.• Developed a clinical resource guide for skin and wound care that quickly became the #1 requested literature item among 1,200 resources. This enabled sales colleagues to support protocol compliance, provide education, and drive cross-portfolio sales initiatives.• Identified an opportunity to influence post-surgical protocols by leading the development of a surgical slide kit. This was utilized by key opinion leaders and the sales force to educate stakeholders, share impactful cases, and effectively promote our products.

Product Manager, ChapStick® Lip Balm • Developed the idea, the strategy to drive incremental product placement, and completed the transaction to license Disney properties (e.g. Princesses, Mickey Mouse, Winnie the Pooh) which achieved the highest year-1 sales for any ChapStick new product franchise.• Launched the Discover the Magic campaign across key retailers which highlighted the universal awareness and positive associations with Disney characters which appeal to kids and parents, and which drive impulse and incremental sales via creative display options. • Introduced a highly compelling “Flower” advertisement which enabled the franchise to exceed budget by boosting the brand’s overall consumer engagement and drove significant sales increases of ChapStick® All Natural +61% and ChapStick® Lip Moisturizer +44%.• Implemented a new trade incentive for Walmart, Walgreens, CVS, Kroger, and other customers which drove incremental product placements across the store (e.g. registers, endcaps, in the lip category aisle, near cosmetics, and pharmacy). Product Manager, Advil® Pain Reliever • Successfully completed the marketing section for two Advil® PM New Drug Applications (NDAs) for Liquid Filled Capsules and Caplets.• Collaborated with Medical to develop and test competitive claims via a market research claim sort study, resulting in a claim that increased purchase interest by 38% compared to the previous claim.• Developed a pricing strategy to minimize cannibalization of existing Advil products and address potential cost of goods challenges. Implemented a premium pricing model per pill with fewer pills per bottle to optimize profitability.Associate Product Manager, Anbesol® Anesthetic • Grew factory and retail sales 15% while reducing SKUs 50% driven by key findings from an in-store packaging research test.• Overcame a 7-point share gap in six months to pass Orajel as the #1 adult toothache product in the anesthetic category.